Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis
Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose dis...
Ausführliche Beschreibung
Autor*in: |
Shima, Yoshihito [verfasserIn] Tomita, Tetsuya [verfasserIn] Ishii, Taeko [verfasserIn] Morishima, Atsuyoshi [verfasserIn] Maeda, Yuichi [verfasserIn] Ogata, Atsushi [verfasserIn] Kishimoto, Tadamitsu [verfasserIn] Tanaka, Toshio [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2011 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Modern rheumatology - Oxford : Oxford University Press, 2000, 21(2011), 4 vom: 09. Feb., Seite 436-439 |
---|---|
Übergeordnetes Werk: |
volume:21 ; year:2011 ; number:4 ; day:09 ; month:02 ; pages:436-439 |
Links: |
---|
DOI / URN: |
10.1007/s10165-011-0416-9 |
---|
Katalog-ID: |
SPR009024565 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR009024565 | ||
003 | DE-627 | ||
005 | 20230519115559.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201005s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10165-011-0416-9 |2 doi | |
035 | |a (DE-627)SPR009024565 | ||
035 | |a (SPR)s10165-011-0416-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.83 |2 bkl | ||
100 | 1 | |a Shima, Yoshihito |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. | ||
650 | 4 | |a Ankylosing spondylitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a IL-6 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Tocilizumab |7 (dpeaa)DE-He213 | |
700 | 1 | |a Tomita, Tetsuya |e verfasserin |4 aut | |
700 | 1 | |a Ishii, Taeko |e verfasserin |4 aut | |
700 | 1 | |a Morishima, Atsuyoshi |e verfasserin |4 aut | |
700 | 1 | |a Maeda, Yuichi |e verfasserin |4 aut | |
700 | 1 | |a Ogata, Atsushi |e verfasserin |4 aut | |
700 | 1 | |a Kishimoto, Tadamitsu |e verfasserin |4 aut | |
700 | 1 | |a Tanaka, Toshio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Modern rheumatology |d Oxford : Oxford University Press, 2000 |g 21(2011), 4 vom: 09. Feb., Seite 436-439 |w (DE-627)320627497 |w (DE-600)2023498-3 |x 1439-7609 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2011 |g number:4 |g day:09 |g month:02 |g pages:436-439 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10165-011-0416-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_267 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
936 | b | k | |a 44.83 |q ASE |
951 | |a AR | ||
952 | |d 21 |j 2011 |e 4 |b 09 |c 02 |h 436-439 |
author_variant |
y s ys t t tt t i ti a m am y m ym a o ao t k tk t t tt |
---|---|
matchkey_str |
article:14397609:2011----::oiiuaauaieatitreknrcpoatbdaeirtdlnclyposnmiidnsf |
hierarchy_sort_str |
2011 |
bklnumber |
44.83 |
publishDate |
2011 |
allfields |
10.1007/s10165-011-0416-9 doi (DE-627)SPR009024565 (SPR)s10165-011-0416-9-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shima, Yoshihito verfasserin aut Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 Tomita, Tetsuya verfasserin aut Ishii, Taeko verfasserin aut Morishima, Atsuyoshi verfasserin aut Maeda, Yuichi verfasserin aut Ogata, Atsushi verfasserin aut Kishimoto, Tadamitsu verfasserin aut Tanaka, Toshio verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 21(2011), 4 vom: 09. Feb., Seite 436-439 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:21 year:2011 number:4 day:09 month:02 pages:436-439 https://dx.doi.org/10.1007/s10165-011-0416-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 21 2011 4 09 02 436-439 |
spelling |
10.1007/s10165-011-0416-9 doi (DE-627)SPR009024565 (SPR)s10165-011-0416-9-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shima, Yoshihito verfasserin aut Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 Tomita, Tetsuya verfasserin aut Ishii, Taeko verfasserin aut Morishima, Atsuyoshi verfasserin aut Maeda, Yuichi verfasserin aut Ogata, Atsushi verfasserin aut Kishimoto, Tadamitsu verfasserin aut Tanaka, Toshio verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 21(2011), 4 vom: 09. Feb., Seite 436-439 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:21 year:2011 number:4 day:09 month:02 pages:436-439 https://dx.doi.org/10.1007/s10165-011-0416-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 21 2011 4 09 02 436-439 |
allfields_unstemmed |
10.1007/s10165-011-0416-9 doi (DE-627)SPR009024565 (SPR)s10165-011-0416-9-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shima, Yoshihito verfasserin aut Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 Tomita, Tetsuya verfasserin aut Ishii, Taeko verfasserin aut Morishima, Atsuyoshi verfasserin aut Maeda, Yuichi verfasserin aut Ogata, Atsushi verfasserin aut Kishimoto, Tadamitsu verfasserin aut Tanaka, Toshio verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 21(2011), 4 vom: 09. Feb., Seite 436-439 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:21 year:2011 number:4 day:09 month:02 pages:436-439 https://dx.doi.org/10.1007/s10165-011-0416-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 21 2011 4 09 02 436-439 |
allfieldsGer |
10.1007/s10165-011-0416-9 doi (DE-627)SPR009024565 (SPR)s10165-011-0416-9-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shima, Yoshihito verfasserin aut Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 Tomita, Tetsuya verfasserin aut Ishii, Taeko verfasserin aut Morishima, Atsuyoshi verfasserin aut Maeda, Yuichi verfasserin aut Ogata, Atsushi verfasserin aut Kishimoto, Tadamitsu verfasserin aut Tanaka, Toshio verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 21(2011), 4 vom: 09. Feb., Seite 436-439 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:21 year:2011 number:4 day:09 month:02 pages:436-439 https://dx.doi.org/10.1007/s10165-011-0416-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 21 2011 4 09 02 436-439 |
allfieldsSound |
10.1007/s10165-011-0416-9 doi (DE-627)SPR009024565 (SPR)s10165-011-0416-9-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shima, Yoshihito verfasserin aut Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 Tomita, Tetsuya verfasserin aut Ishii, Taeko verfasserin aut Morishima, Atsuyoshi verfasserin aut Maeda, Yuichi verfasserin aut Ogata, Atsushi verfasserin aut Kishimoto, Tadamitsu verfasserin aut Tanaka, Toshio verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 21(2011), 4 vom: 09. Feb., Seite 436-439 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:21 year:2011 number:4 day:09 month:02 pages:436-439 https://dx.doi.org/10.1007/s10165-011-0416-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 21 2011 4 09 02 436-439 |
language |
English |
source |
Enthalten in Modern rheumatology 21(2011), 4 vom: 09. Feb., Seite 436-439 volume:21 year:2011 number:4 day:09 month:02 pages:436-439 |
sourceStr |
Enthalten in Modern rheumatology 21(2011), 4 vom: 09. Feb., Seite 436-439 volume:21 year:2011 number:4 day:09 month:02 pages:436-439 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Ankylosing spondylitis IL-6 Tocilizumab |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Modern rheumatology |
authorswithroles_txt_mv |
Shima, Yoshihito @@aut@@ Tomita, Tetsuya @@aut@@ Ishii, Taeko @@aut@@ Morishima, Atsuyoshi @@aut@@ Maeda, Yuichi @@aut@@ Ogata, Atsushi @@aut@@ Kishimoto, Tadamitsu @@aut@@ Tanaka, Toshio @@aut@@ |
publishDateDaySort_date |
2011-02-09T00:00:00Z |
hierarchy_top_id |
320627497 |
dewey-sort |
3610 |
id |
SPR009024565 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009024565</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115559.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-011-0416-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009024565</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-011-0416-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shima, Yoshihito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ankylosing spondylitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-6</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tocilizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomita, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishii, Taeko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morishima, Atsuyoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maeda, Yuichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogata, Atsushi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kishimoto, Tadamitsu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Toshio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">21(2011), 4 vom: 09. Feb., Seite 436-439</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">day:09</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:436-439</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-011-0416-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="b">09</subfield><subfield code="c">02</subfield><subfield code="h">436-439</subfield></datafield></record></collection>
|
author |
Shima, Yoshihito |
spellingShingle |
Shima, Yoshihito ddc 610 bkl 44.83 misc Ankylosing spondylitis misc IL-6 misc Tocilizumab Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
authorStr |
Shima, Yoshihito |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)320627497 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1439-7609 |
topic_title |
610 ASE 44.83 bkl Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis Ankylosing spondylitis (dpeaa)DE-He213 IL-6 (dpeaa)DE-He213 Tocilizumab (dpeaa)DE-He213 |
topic |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc IL-6 misc Tocilizumab |
topic_unstemmed |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc IL-6 misc Tocilizumab |
topic_browse |
ddc 610 bkl 44.83 misc Ankylosing spondylitis misc IL-6 misc Tocilizumab |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Modern rheumatology |
hierarchy_parent_id |
320627497 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Modern rheumatology |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)320627497 (DE-600)2023498-3 |
title |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
ctrlnum |
(DE-627)SPR009024565 (SPR)s10165-011-0416-9-e |
title_full |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
author_sort |
Shima, Yoshihito |
journal |
Modern rheumatology |
journalStr |
Modern rheumatology |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2011 |
contenttype_str_mv |
txt |
container_start_page |
436 |
author_browse |
Shima, Yoshihito Tomita, Tetsuya Ishii, Taeko Morishima, Atsuyoshi Maeda, Yuichi Ogata, Atsushi Kishimoto, Tadamitsu Tanaka, Toshio |
container_volume |
21 |
class |
610 ASE 44.83 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Shima, Yoshihito |
doi_str_mv |
10.1007/s10165-011-0416-9 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and mri findings of a patient with ankylosing spondylitis |
title_auth |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
abstract |
Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. |
abstractGer |
Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. |
abstract_unstemmed |
Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 |
container_issue |
4 |
title_short |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis |
url |
https://dx.doi.org/10.1007/s10165-011-0416-9 |
remote_bool |
true |
author2 |
Tomita, Tetsuya Ishii, Taeko Morishima, Atsuyoshi Maeda, Yuichi Ogata, Atsushi Kishimoto, Tadamitsu Tanaka, Toshio |
author2Str |
Tomita, Tetsuya Ishii, Taeko Morishima, Atsuyoshi Maeda, Yuichi Ogata, Atsushi Kishimoto, Tadamitsu Tanaka, Toshio |
ppnlink |
320627497 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s10165-011-0416-9 |
up_date |
2024-07-04T00:21:57.305Z |
_version_ |
1803605788387704833 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009024565</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115559.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-011-0416-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009024565</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-011-0416-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shima, Yoshihito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ankylosing spondylitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-6</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tocilizumab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomita, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishii, Taeko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morishima, Atsuyoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maeda, Yuichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogata, Atsushi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kishimoto, Tadamitsu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Toshio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">21(2011), 4 vom: 09. Feb., Seite 436-439</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">day:09</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:436-439</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-011-0416-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="b">09</subfield><subfield code="c">02</subfield><subfield code="h">436-439</subfield></datafield></record></collection>
|
score |
7.401602 |